Connect with Us
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2023 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.
Renu Juneja
Renu Juneja is Head of Scientific Evidence and Communications at Janssen Biotechnology Inc (JBI). Her team has the responsibility for publication plans, medical education, medical booth content, KOL engagements, MSL slide decks & training, cooperative studies and clinical trial operations in Oncology Medical affairs at JBI. Before joining Janssen, Renu was head of the Medical Communications group at MedImmune (the worldwide biologics research and development arm of AstraZeneca). Her group had the responsibility for both regulatory documents and development & execution of strategic publication plans. Her team supported all therapeutic areas including Immuno-oncology, respiratory, inflammation, CVMD, infectious diseases and vaccines.
Previously, she led the Strategic Scientific Communication (SSC) group at Novo Nordisk Inc. (NNI). She also had the opportunity to lead the Information & Education group at NNI and was responsible for the company’s library and for Independent Medical Education (IMEs) programs. Renu started her career in Novo Nordisk as a medical writer. After finishing her PhD in Reproductive Biology & Biochemistry from the Post-Graduate Institute of Medical Education & Research (PGIMER) in India, Renu joined The Population Council in NY as a Postdoctoral fellow. Two years later, she received an independent research grant from the Lalor Foundation and joined the department of Molecular Biology at the Princeton University. She has over 30 publications in peer-reviewed journals and has presented at various national and international conferences.
Renu has presented and conducted workshops at the annual meetings of various professional organizations e.g. ISMPP, TIPPA, CBI, and Q1 productions.
Fatima Ahmad
Fatima Ahmad, PharmD is Vice President of Medical Affairs at Castle Creek Biosciences, a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. Previously, she held positions at Spark Therapeutics, a member of the Roche group, including heading the Medical Communications team responsible for leading integrated Medical Communications Strategies across therapeutic areas in Spark’s portfolio of AAV-based investigational gene therapies, as well as serving as Therapeutic Area Leader for hematology. Previously, Fatima spent time at Advaxis Immunotherapies as Senior Director Medical Affairs and at Otsuka Pharmaceuticals, where she held roles of increasing seniority in US and Global Medical Affairs.
Fatima began her industry career at AstraZeneca where she was a Pharmacy intern and subsequently held roles in Medical Information and Medical Communication Science, working across several therapeutic areas including respiratory and oncology. She graduated Magna Cum Laude from Temple University with a PharmD degree, and practiced community pharmacy briefly before transitioning to the pharmaceutical industry. Fatima is passionate about incorporating a patient-centric approach to all aspects of Medical Affairs and is committed to the evolution of Medical Affairs in best serving patients in the era of personalized medicine and novel therapeutic modalities.